Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Kohlmann

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Blood|May 12, 2009
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresClaudia Haferlach, Cristina Mecucci, Susanne Schnittger, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|August 24, 2012
A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann, Susanne Schnittger, Alexander Kohlmann, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2014
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phaseKaterina Machova Polakova, Vojtech Kulvait, Adela Benesova, et al.
Plos One|April 9, 2024
Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubesTheresa May, Michelle S Clement, Harkanwal Halait, et al.
ESMO Open|October 12, 2017
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceJames L Sherwood, Helen Brown, Alessandro Rettino, et al.
Leukemia Research|February 22, 2017
A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblastsKamila Janusz, Mónica Del Rey, María Abáigar, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro DiagnosticJhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Nature Communications|January 15, 2015
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndromeVikas Madan, Deepika Kanojia, Jia Li, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Blood|August 25, 2012
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Blood|May 12, 2009
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic featuresClaudia Haferlach, Cristina Mecucci, Susanne Schnittger, et al.
Blood|May 16, 2009
Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndromeKen I Mills, Alexander Kohlmann, P Mickey Williams, et al.
Blood|August 24, 2012
A novel hierarchical prognostic model of AML solely based on molecular mutationsVera Grossmann, Susanne Schnittger, Alexander Kohlmann, et al.
Journal of Cancer Research and Clinical Oncology|November 5, 2014
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phaseKaterina Machova Polakova, Vojtech Kulvait, Adela Benesova, et al.
Plos One|April 9, 2024
Performance characteristics of a polymerase chain reaction-based assay for the detection of EGFR mutations in plasma cell-free DNA from patients with non-small cell lung cancer using cell-free DNA collection tubesTheresa May, Michelle S Clement, Harkanwal Halait, et al.
ESMO Open|October 12, 2017
Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practiceJames L Sherwood, Helen Brown, Alessandro Rettino, et al.
Leukemia Research|February 22, 2017
A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblastsKamila Janusz, Mónica Del Rey, María Abáigar, et al.
The Journal of Molecular Diagnostics : JMD|November 19, 2023
Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro DiagnosticJhanelle E Gray, Ji-Youn Han, Aino Telaranta-Keerie, et al.
Nature Communications|January 15, 2015
Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndromeVikas Madan, Deepika Kanojia, Jia Li, et al.
Pageof 11